Shares of Globus Medical, Inc. (NYSE:GMED – Get Free Report) gapped down prior to trading on Friday after an insider sold shares in the company. The stock had previously closed at $81.44, but opened at $74.10. Globus Medical shares last traded at $72.6550, with a volume of 1,538,117 shares traded.
Specifically, Director Ann Rhoads sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the transaction, the director owned 35,384 shares in the company, valued at approximately $3,007,640. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Analysts Set New Price Targets
GMED has been the subject of a number of recent research reports. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Friday. Royal Bank Of Canada lowered their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. UBS Group initiated coverage on Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target for the company. Finally, Truist Financial reduced their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.00.
Get Our Latest Stock Report on Globus Medical
Key Headlines Impacting Globus Medical
Here are the key news stories impacting Globus Medical this week:
- Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and above $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, potentially supporting shareholder returns. Third-quarter results and repurchase program
- Positive Sentiment: Needham lowered its price target from $117 to $100 but maintained a Buy rating. The revised target remains above the cited share price of $81.13. Needham analyst recommendations
- Positive Sentiment: The reported acquisition of Synaptive Medical may broaden Globus’s cranial-neurosurgery technology and strengthen its position in that market. Synaptive Medical acquisition
- Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38%. One director’s sale does not by itself establish a change in the company’s outlook. Director share sale
- Negative Sentiment: Revenue of $763.7 million missed the $792.4 million consensus and fell 0.7% year over year. Full-year revenue guidance of $3.1 billion is below the $3.2 billion analyst estimate, while EPS guidance of $4.95–$5.05 is broadly in line with expectations. Quarterly results and guidance
- Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target from $94 to $78, citing a more cautious view of the shares. BMO analyst recommendations
Globus Medical Stock Performance
The business’s 50-day moving average is $77.44 and its 200 day moving average is $83.29. The company has a market cap of $9.75 billion, a PE ratio of 18.71, a PEG ratio of 1.40 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last issued its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. Globus Medical’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities research analysts anticipate that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.
Institutional Trading of Globus Medical
Large investors have recently modified their holdings of the business. Washington Trust Advisors Inc. grew its position in Globus Medical by 116.8% in the 2nd quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock worth $3,556,000 after purchasing an additional 24,250 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Globus Medical during the 2nd quarter valued at approximately $1,858,000. WCM Investment Management LLC bought a new stake in Globus Medical in the 1st quarter valued at $16,965,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Globus Medical in the second quarter worth about $7,941,000. Finally, Congress Asset Management Co. boosted its position in shares of Globus Medical by 6.6% during the 3rd quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock valued at $27,041,000 after acquiring an additional 22,401 shares during the last quarter. 95.16% of the stock is owned by institutional investors.
Globus Medical Company Profile
Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.
Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.
Featured Stories
- Five stocks we like better than Globus Medical
- Arista Networks Cashes In on the AI Infrastructure Buildout
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
